Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

213 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Special considerations for the treatment of multiple myeloma according to advanced age, comorbidities, frailty and organ dysfunction.
Fraz MA, Warraich FH, Warraich SU, Tariq MJ, Warraich Z, Khan AY, Usman M, Ijaz A, Tenneti P, Mushtaq A, Akbar F, Shahid Z, Ali Z, Fazeel HM, Rodriguez C, Nasar A, McBride A, Anwer F. Fraz MA, et al. Among authors: anwer f. Crit Rev Oncol Hematol. 2019 May;137:18-26. doi: 10.1016/j.critrevonc.2019.02.011. Epub 2019 Feb 27. Crit Rev Oncol Hematol. 2019. PMID: 31014512 Free PMC article. Review.
Future of Personalized Therapy Targeting Aberrant Signaling Pathways in Multiple Myeloma.
Anwer F, Gee KM, Iftikhar A, Baig M, Russ AD, Saeed S, Zar MA, Razzaq F, Carew J, Nawrocki S, Al-Kateb H, Cavalcante Parr NN, McBride A, Valent J, Samaras C. Anwer F, et al. Clin Lymphoma Myeloma Leuk. 2019 Jul;19(7):397-405. doi: 10.1016/j.clml.2019.03.017. Epub 2019 Mar 25. Clin Lymphoma Myeloma Leuk. 2019. PMID: 31036508 Free PMC article. Review.
Pomalidomide-Based Regimens for Treatment of Relapsed and Relapsed/Refractory Multiple Myeloma: Systematic Review and Meta-analysis of Phase 2 and 3 Clinical Trials.
Mushtaq A, Iftikhar A, Hassan H, Lakhani M, Sagar F, Kamal A, Zahid U, Ali Z, Razzaq F, Zar MA, Hassan SF, Safdar A, Raychaudhuri S, Anwer F. Mushtaq A, et al. Among authors: anwer f. Clin Lymphoma Myeloma Leuk. 2019 Jul;19(7):447-461. doi: 10.1016/j.clml.2019.04.003. Epub 2019 Apr 6. Clin Lymphoma Myeloma Leuk. 2019. PMID: 31060991
Treatment of relapsed multiple myeloma: Evidence-based recommendations.
Durer C, Durer S, Lee S, Chakraborty R, Malik MN, Rafae A, Zar MA, Kamal A, Rosko N, Samaras C, Valent J, Chaulagain C, Anwer F. Durer C, et al. Among authors: anwer f. Blood Rev. 2020 Jan;39:100616. doi: 10.1016/j.blre.2019.100616. Epub 2019 Aug 31. Blood Rev. 2020. PMID: 31500848 Review.
Therapeutic Advances in the Management of Smoldering Myeloma.
Khan R, Zahid U, Kollu V, Jahan N, Ali M, Tricot G, Anwer F. Khan R, et al. Among authors: anwer f. Am J Ther. 2020 Mar/Apr;27(2):e194-e203. doi: 10.1097/MJT.0000000000001034. Am J Ther. 2020. PMID: 31842112 Review.
Venous thromboembolism risk with contemporary lenalidomide-based regimens despite thromboprophylaxis in multiple myeloma: A systematic review and meta-analysis.
Chakraborty R, Bin Riaz I, Malik SU, Marneni N, Mejia Garcia A, Anwer F, Khorana AA, Rajkumar SV, Kumar S, Murad MH, Wang Z, Khan SU, Majhail NS. Chakraborty R, et al. Among authors: anwer f. Cancer. 2020 Apr 15;126(8):1640-1650. doi: 10.1002/cncr.32682. Epub 2020 Jan 8. Cancer. 2020. PMID: 31913498 Free PMC article.
213 results